ScripBayer’s bid to maintain its lead in the anti-vascular endothelial growth factor (VEGF) eye disease space has received a boost with a fresh approval in Europe that extends the intervals between injecti
ScripPfizer stands to expand the addressable market for its hemophilia A and B drug Hympavzi (marstacimab-hncq) with Phase III data showing it is effective in patients with clotting factor inhibitors along
ScripBiogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on Ju
ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C